Taysha Gene Therapies (TSHA) Operating Income (2022 - 2025)
Historic Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$34.0 million.
- Taysha Gene Therapies' Operating Income fell 3137.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 1635.7%. This contributed to the annual value of -$91.5 million for FY2024, which is 2625.66% down from last year.
- Per Taysha Gene Therapies' latest filing, its Operating Income stood at -$34.0 million for Q3 2025, which was down 3137.69% from -$26.8 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Operating Income peaked at -$16.2 million during Q4 2023, and registered a low of -$54.0 million during Q4 2022.
- Over the past 4 years, Taysha Gene Therapies' median Operating Income value was -$24.3 million (recorded in 2024), while the average stood at -$27.2 million.
- In the last 5 years, Taysha Gene Therapies' Operating Income surged by 6989.59% in 2023 and then plummeted by 5937.23% in 2024.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Operating Income stood at -$54.0 million in 2022, then surged by 69.9% to -$16.2 million in 2023, then fell by 22.69% to -$19.9 million in 2024, then crashed by 70.7% to -$34.0 million in 2025.
- Its last three reported values are -$34.0 million in Q3 2025, -$26.8 million for Q2 2025, and -$21.4 million during Q1 2025.